 |
Roger Lo, MD, PhD
Specialty
Dermatology
Dermatology
Gender
Male
Male
Language Spoken
English, Mandarin
English, Mandarin
Hospital Affiliation
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
State License Number
A84131
A84131
Contact
(310) 917-3376 Information and referral
(310) 917-3376 Information and referral
Fax Number
(310) 794-7005
(310) 794-7005
PRACTICE LOCATION
UCLA Dermatology
200 Peter Morton Medical Plaza, Suite 450
Los Angeles, CA 90095
200 Peter Morton Medical Plaza, Suite 450
Los Angeles, CA 90095
MEDICAL BOARD CERTIFICATION
Dermatology, American Board of Dermatology, 2007
EDUCATION
Residency
Dermatology, UCLA School of Medicine, 2003 - 2006
Dermatology, UCLA School of Medicine, 2003 - 2006
Internship
Internal Medicine, St. Vincent's Hospital and Medical Center of NY, 2002 - 2003
Internal Medicine, St. Vincent's Hospital and Medical Center of NY, 2002 - 2003
Medical Degree
MD, Weill Cornell Medical College, 2002
MD, Weill Cornell Medical College, 2002
CLINICAL INTEREST
| Melanoma, Nevi (moles), Skin Cancer |
AFFILIATION
MORE INFORMATION
Research Interest
Melanoma, dysplastic nevus syndrome, familial melanoma, Targeted therapy of advanced melanoma, Drug resistance to targeted therapy
Awards & Recognition
- 33th Annual Award for Outstanding Achievement in Cancer Research, American Association for Cancer Research, 2013
- First Place, Department of Medicine Research Day 2012, UCLA Election (member) to the American Society for Clinical Investigation (ASCI), 2012
- Scholar in Translational Medicine, Broad Center for Stem Cell Research, UCLA, 2011 ? Bud Selig Innovative Research Grant (IRG), Stand Up to Cancer, 2011
- Sidney Kimmel Translational Scholar, Sidney Kimmel Foundation, 2011
- Young Investigator Award, Melanoma Research Alliance, 2011
- Researcher of the Year Award, Melanoma International Foundation, 2011
- Team Science Award, Melanoma Research Alliance, 2010
- Translation Acceleration Award, Caltech-UCLA Joint Center for Translational Medicine (Inaugural Grant), 2010
- Junior Investigator Award, Melanoma Research Foundation, 2010
- Abby S. and Howard P. Milstein Research Scholar Award, American Skin Association, 2010
- V Scholar Award, V Foundation for Cancer Research, 2009
- Research Development Award, STOP CANCER Foundation, 2008
- American Association for Cancer Research-Aflac, Inc. Scholar-in-Training Award, 2008
- Career Award for Medical Scientists (CAMS), Burroughs Wellcome Fund, 2007
- UCLA Department of Medicine Research Day Poster Competition. Second Place, 2007
- Physician-Scientist Career Award, Dermatology Foundation, 2007
- UCLA Department of Medicine Research Day Poster Competition, First Place, 2006
- Victor D. Newcomer Award and Lecture, 58th Annual Meeting, Pacific Dermatologic Association, 2006
- Future Physician-Scientist, Society for Investigative Dermatology, 2004
- Julian R. Rachele Prize, Weill Cornell Graduate School of Medical Sciences (highest prize for Ph.D. doctoral thesis), 2001
- Firestone Medal for Excellence in Research, Stanford University (highest prize for undergraduate honors thesis), 1994
- American Gastroenterology Association Student Investigator Prize, Digestive Disease Week 1994
- Howard Hughes Medical Institute (HHMI) Major Grants for Undergraduate Research, 1992 & 1993
- American Gastroenterology Association Student Research Fellowship, 1991
- First Place, Orange County Science Fair, 1989
- Southern California Junior Academy of Science Research Fellowship, 1988
Publications
1. R. S. Lo, H. Said, T. Unger, D. Hollander, and R. Miledi (1991) An endogenous carrier-mediated uptake system for folate in oocytes of Xenopus laevis, Proceedings of the Royal Society of London, Series B. 246, 161-165.
2. G. Cox, S. Matsui, R. S. Lo et. al., (1994) Etiology and outcome of diarrhea after marrow transplantation: a prospective study, Gastroenterology, 107, 1398-1407.
3. R. S. Lo, I. Sekler, T. Mastrocola, and R.R. Kopito (1995) Sulfate transport mediated by the mammalian anion exchangers in reconstituted proteoliposomes, Journal of Biologic Chemistry, 270 (19), 11251-11256.
4. R. S. Lo, I. Sekler, and R.R. Kopito (1995) A conserved glutamate is responsible for ion selectivity and pH dependence of the mammalian anion exchangers AE1 and AE2, Journal of Biologic Chemistry, 270 (48), 28751-28758.
5. Hata, R. S. Lo, D. Wotton, G. Lagna, and J. Massagué (1997) Mutations increasing auto-inhibition inactivate the tumour suppressors Smad2 and Smad4, Nature, 388, 82-87. (News & Views in the same issue)
6. Y. Shi, A. Hata, R. S. Lo, J. Massagué, and N. Pavletich (1997) A structural basis for mutational inactivation of the tumour suppressor Smad4, Nature, 388, 87-93. (News & Views in the same issue)
7. R. S. Lo, Y-G Chen, Y. Shi, N. P. Pavletich and J. Massagué (1998) The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-? receptors, EMBO Journal, 17, 996-1005.
8. Y-G Chen, A. Hata, R. S. Lo, D. Wotton, Y. Shi, N. Pavletich and J. Massagué (1998) Determinants of specificity in TGF-? signal transduction, Genes & Development, 12, 2144-2152.
9. D. Wotton, R. S. Lo, S. Lee and J. Massagué (1999) A Smad transcriptional corepressor, Cell, 97, 29-39.
10. R. S. Lo and J. Massagué (1999) Ubiquitin-dependent degradation of TGF-?-activated Smad2, Nature Cell Biology, 1, 472-478. (News & Views in the same issue)
11. B. Pasche, P. Kolachana, K. Nafa, J. Satagopan, Y-G Chen, R. S. Lo et. al., (1999) T?R-I(6A) is a candidate tumor susceptibility allele, Cancer Research, 59, 5678-5682.
12. D. Wotton, R. S. Lo, L. C. Swaby and J. Massagué (1999) Multiple modes of repression by the Smad transcriptional corepressor TGIF, Journal of Biologic Chemistry, 274, 37105-37110.
13. R. S. Lo, D. Wotton, and J. Massagué (2001) Ras signaling controls the Smad transcriptional corepressor TGIF, EMBO Journal, 20, 128-136.
14. R. S. Lo and O. N. Witte (2008) Transforming growth factor-? activation promotes genetic context-dependent invasion of immortalized melanocytes, Cancer Research, 68(11), 4248-57.
15. J. N. Søndergaard, R. Nazarian, Q. Wang, S. Mok, H. Sazegar, T. Hsueh, S. Kehoe, L. Macconaill, J. Borretina, N. Attar, J. Zuckerman, B. Chmielowski, B. Comin-Anduix, R. Koya, G. Bollag, P. Mischel, R. S. Lo, A. Ribas (2010) Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific BRAF V600E inhibitor PLX4032/RO5185426, Journal of Translational Medicine, 8, 39.
16. R. Nazarian, H. Shi, Q. Wang, X. Kong, R. C. Koya, H. Lee, Z. Chen, M. Lee, N. Attar, H. Sazegar, S. F. Nelson, G. McArthur, J. A. Sosman, A. Ribas and R. S. Lo (2010) Melanomas acquire resistance to V600EB-RAF inhibition by RTK or N-RAS upregulation, Nature, 2010 468(7326):973-7 (News & Views in the same issue) (cited 470 times from Dec 2010 to Mar 2013).
17. F. Niehr, E. Euw, N. Attar, D. Guo, D. Matsunaga, H. Sazegar, C. Ng, J. A. Glaspy, R. S. Lo, P. S. Mischel, B. Comin-Anduix, A. Ribas (2011) Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations, Journal of Translational Medicine, 9(1):76.
18. H. Shi, X. Kong, A. Ribas, and R. S. Lo (2011) Combinatorial treatments that overcome PDGFR?-driven resistance of melanoma cells to V600EB-RAF inhibition, Cancer Research (Priority Report), 71(15):5067-74.
19. M. Atefi, E. Euw, N. Attar, C. Chu, D.Guo, R. Nazarian, B. Chmielowski, J. A. Glaspy, P. Mischel, R. S. Lo, and A. Ribas (2011) Reversing cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway, PLOS ONE, 6(12):e28973. Epub 2011 Dec 14.
20. P. I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, G. Moriceau, H. Shi, M. Atefi, B. Titz, M. Gabay, M. Salton, K. Dahlman, T. Madhavi, J. A. Wargo, K. T. Flaherty, M. C. Kelley, T. Misteli, J. A. Sosman, P. Chapman, T. G. Graeber, A. Ribas, R. S. Lo, N. Rosen, D. B. Solit (2011) Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF (V600E) that dimerize in a RAS independent manner, Nature, Nov 23 480(7377):387-390 (News & Views in the same issue).
21. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, O. Spleiss, J. S. Reis-Filho, X. Kong, R. C. Koya, M. J. Kim, R. Hayward, M. Martin, H. Yang, Q. Wang, J. Noe, M. Lambros, F. Geyer, N. Dhomen, I. Niculescu-Duvaz, A. Zambon, D. Niculescu-Duvaz, N. Preece, L. Robert, N. J. Otte, S. Mok, D. Kee, Y. Ma, C. Zhang G. Habets, E. A. Burton, B. Wong, H. Nguyen, J. L. Troy, K. T. Flaherty, P. B. Chapman, R. Gonzalez, T. E. Hutson, I. Puzanov, B. Lestini, K. B. Nolop, R. J. Lee, A. K. Joe, C. J. Springer, J. A. Sosman, G. McArthu, R. S. Lo, A. Ribas, R. Marais (2012) RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors, New England Journal of Medicine, Jan 19 366(3):207-15 (Editorial in the same issue).
22. H. Shi, G. Moriceau, X. Kong, M-K Lee, F. Lee, R. C. Koya, C. Ng, T. Chodon, G. M. Pupo, K. Dahlman, J. A. Sosman, R. F. Kefford, G. V. Long, S. F. Nelson, A. Ribas, R. S. Lo (2012) Melanoma whole exome sequencing identifies gene amplification-mediated acquired resistance to vemurafenib, Nature Communications, Mar 6;3:a724. doi: 10.1038/ncomms1727 (News & Views in the same issue).
23. K.T. Paraiso, H.E. Haarberg, E. Wood, V.W.Rebecca, Y.A. Chen, Y. Xiang, A. Ribas, R. S. Lo, J.S. Weber, V.K. Sondak, J.K. John, A.S. Sarnaik, J.M. Koomen, K.S. Smalley (2012) The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms, Clinical Cancer Research, Feb 20. [Epub ahead of print].
24. H. Shi, G. Moriceau, X. Kong, R. Koya, R. Nazarian, A. Bacchiocchi, K. Dahlman, J. A. Sosman, R. Halaban, R. Kefford, G. V. Long, A. Ribas, and R. S. Lo (2012) Pre-existing MEK1 exon 3 mutations in V600E/KB-RAF melanomas do not confer resistance to B-RAF inhibitors, Cancer Discovery, May;2(5):414-424. Epub 2012 Apr 1. (In This Issue highlight).
25. N. A. Graham, M. Tahmasian, B. Kohli, E. Komisopoulou, M. Zhu, A. Ribas, R. S. Lo, I. K. Mellinghoff, P. S. Mischel and T. G. Graeber (2012) Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death, Molecular Systems Biology, Jun 26;8:589.
26. R. Strausman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub (2012) Tumor microenviroment contributes to RAF-inhibitor resistance through HGF secretion, Nature, 487(7408):500-4.
27. M. Krauthammer, Y. Kong, P. Evans, M. Choi, A. Bacchiocchi, B. Ha, J. P. McCusker, E. Cheng, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Raefski, M. Bosenberg, M. Sznol, H. M. Kluger, D. E. Brash, D. F. Stern, M. A. Materin, R. S. Lo, S. Mane, S. Ma, K. Kidd, N. K. Hayward, R. P. Lifton, J. Schlessinger, T. J. Boggon, R. Halaban (2012) A recurrent activating UV signature mutation in RAC1 in melanomas, Nature Genetics, Jul 29. doi: 10.1038/ng.2359. [Epub ahead of print]
28. A. Gembarska, F. Luciani, H. Shi, E. Russel, J. de Lange, D. Yip, J. Goydos, J. J. Haigh, L. Larue, A. Jochemsen, H. Shi, G. Moriceau, R. S. Lo, G. Ghanem, F. Bernal, J-C Marine (2012) MDM4 is a key therapeutic target in melanoma, Nature Medicine, Jul 22. doi: 10.1038/nm.2863. [Epub ahead of print]
29. A. Viros, R. Hayward, S. Yashar, C.C. Yu, M. Martin, A. Zambon, D. Niculescu-Duvaz, C. Springer, R. S, Lo and R. Marais (2012) Topical 5-fluorouracil induces regression of keratoacanthoma and squamous cell carcinoma secondary to BRAF inhibitors, Journal of Investigative Dermatology, Aug 16. doi: 10.1038/jid.2012.268. [Epub ahead of print]
30. J. S. Wilmott, V. Tembe, J. R. Howle, R. Sharma, J. F. Thompson, H. Rizos, R. S. Lo, R. F. Kefford, R. A. Scolyer, G. V. Long (2012) Intralesional molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine, Molecular Cancer Therapeutics, Sep 7. [Epub ahead of print].
31. K. Trunzer, A. C. Pavlick, L. Schuchter, R. Gonzalez, G. A. McArthur, T. E. Hutson, S. J. Moschoss, K. T. Flaherty, K. B. Kim, J. S. Weber, P. Hersey, R. Kefford, D. Lawrence, P. Ott, R. Amaravadi, K. Lewis, I. Puzanov, R. S. Lo, A. Koehler, M. Kockx, O. Spleiss, A. Schell-Steven, L. Cockey, K. Nolop, R. Lee, A. Joe, J. A. Sosman, A. Ribas (2013) Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma, Journal of Clinical Oncology, Apr 8. [Epub ahead of print]
32. S. Hou, L. Zhao, Q. Shen, J. Yu, C. Ng, X. Kong, D. Wu, M. Song, X. Shi, Clover X. Xu, W-H. OuYang, R. He, X-Z. Zhao, B. Xiong, T. Lee, C. Brunicardi, M. A. Garcia, A. Ribas, R. S. Lo and H-R. Tseng (2013) Polymer nanofiber-embedded microchips for detection, isolation and molecular analysis of single circulating melanoma cells, Angewandte Chemie, Mar 18;52(12):3379-83. doi: 10.1002/anie.201208452. Epub 2013 Feb 21.
33. R.S. Lo, A. Ribas, G.V. Long, R. Ballotti, M. Berger, H. Willy, G.T. Gibney, M. Bosenberg, E. Bernstein, J. Villanueva, K.S. Smalley (2013) Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California, Pigment Cell Melanoma Research, Apr 4. doi: 10.1111/pcmr.12103. [Epub ahead of print].
2. G. Cox, S. Matsui, R. S. Lo et. al., (1994) Etiology and outcome of diarrhea after marrow transplantation: a prospective study, Gastroenterology, 107, 1398-1407.
3. R. S. Lo, I. Sekler, T. Mastrocola, and R.R. Kopito (1995) Sulfate transport mediated by the mammalian anion exchangers in reconstituted proteoliposomes, Journal of Biologic Chemistry, 270 (19), 11251-11256.
4. R. S. Lo, I. Sekler, and R.R. Kopito (1995) A conserved glutamate is responsible for ion selectivity and pH dependence of the mammalian anion exchangers AE1 and AE2, Journal of Biologic Chemistry, 270 (48), 28751-28758.
5. Hata, R. S. Lo, D. Wotton, G. Lagna, and J. Massagué (1997) Mutations increasing auto-inhibition inactivate the tumour suppressors Smad2 and Smad4, Nature, 388, 82-87. (News & Views in the same issue)
6. Y. Shi, A. Hata, R. S. Lo, J. Massagué, and N. Pavletich (1997) A structural basis for mutational inactivation of the tumour suppressor Smad4, Nature, 388, 87-93. (News & Views in the same issue)
7. R. S. Lo, Y-G Chen, Y. Shi, N. P. Pavletich and J. Massagué (1998) The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-? receptors, EMBO Journal, 17, 996-1005.
8. Y-G Chen, A. Hata, R. S. Lo, D. Wotton, Y. Shi, N. Pavletich and J. Massagué (1998) Determinants of specificity in TGF-? signal transduction, Genes & Development, 12, 2144-2152.
9. D. Wotton, R. S. Lo, S. Lee and J. Massagué (1999) A Smad transcriptional corepressor, Cell, 97, 29-39.
10. R. S. Lo and J. Massagué (1999) Ubiquitin-dependent degradation of TGF-?-activated Smad2, Nature Cell Biology, 1, 472-478. (News & Views in the same issue)
11. B. Pasche, P. Kolachana, K. Nafa, J. Satagopan, Y-G Chen, R. S. Lo et. al., (1999) T?R-I(6A) is a candidate tumor susceptibility allele, Cancer Research, 59, 5678-5682.
12. D. Wotton, R. S. Lo, L. C. Swaby and J. Massagué (1999) Multiple modes of repression by the Smad transcriptional corepressor TGIF, Journal of Biologic Chemistry, 274, 37105-37110.
13. R. S. Lo, D. Wotton, and J. Massagué (2001) Ras signaling controls the Smad transcriptional corepressor TGIF, EMBO Journal, 20, 128-136.
14. R. S. Lo and O. N. Witte (2008) Transforming growth factor-? activation promotes genetic context-dependent invasion of immortalized melanocytes, Cancer Research, 68(11), 4248-57.
15. J. N. Søndergaard, R. Nazarian, Q. Wang, S. Mok, H. Sazegar, T. Hsueh, S. Kehoe, L. Macconaill, J. Borretina, N. Attar, J. Zuckerman, B. Chmielowski, B. Comin-Anduix, R. Koya, G. Bollag, P. Mischel, R. S. Lo, A. Ribas (2010) Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific BRAF V600E inhibitor PLX4032/RO5185426, Journal of Translational Medicine, 8, 39.
16. R. Nazarian, H. Shi, Q. Wang, X. Kong, R. C. Koya, H. Lee, Z. Chen, M. Lee, N. Attar, H. Sazegar, S. F. Nelson, G. McArthur, J. A. Sosman, A. Ribas and R. S. Lo (2010) Melanomas acquire resistance to V600EB-RAF inhibition by RTK or N-RAS upregulation, Nature, 2010 468(7326):973-7 (News & Views in the same issue) (cited 470 times from Dec 2010 to Mar 2013).
17. F. Niehr, E. Euw, N. Attar, D. Guo, D. Matsunaga, H. Sazegar, C. Ng, J. A. Glaspy, R. S. Lo, P. S. Mischel, B. Comin-Anduix, A. Ribas (2011) Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations, Journal of Translational Medicine, 9(1):76.
18. H. Shi, X. Kong, A. Ribas, and R. S. Lo (2011) Combinatorial treatments that overcome PDGFR?-driven resistance of melanoma cells to V600EB-RAF inhibition, Cancer Research (Priority Report), 71(15):5067-74.
19. M. Atefi, E. Euw, N. Attar, C. Chu, D.Guo, R. Nazarian, B. Chmielowski, J. A. Glaspy, P. Mischel, R. S. Lo, and A. Ribas (2011) Reversing cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway, PLOS ONE, 6(12):e28973. Epub 2011 Dec 14.
20. P. I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, G. Moriceau, H. Shi, M. Atefi, B. Titz, M. Gabay, M. Salton, K. Dahlman, T. Madhavi, J. A. Wargo, K. T. Flaherty, M. C. Kelley, T. Misteli, J. A. Sosman, P. Chapman, T. G. Graeber, A. Ribas, R. S. Lo, N. Rosen, D. B. Solit (2011) Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF (V600E) that dimerize in a RAS independent manner, Nature, Nov 23 480(7377):387-390 (News & Views in the same issue).
21. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, O. Spleiss, J. S. Reis-Filho, X. Kong, R. C. Koya, M. J. Kim, R. Hayward, M. Martin, H. Yang, Q. Wang, J. Noe, M. Lambros, F. Geyer, N. Dhomen, I. Niculescu-Duvaz, A. Zambon, D. Niculescu-Duvaz, N. Preece, L. Robert, N. J. Otte, S. Mok, D. Kee, Y. Ma, C. Zhang G. Habets, E. A. Burton, B. Wong, H. Nguyen, J. L. Troy, K. T. Flaherty, P. B. Chapman, R. Gonzalez, T. E. Hutson, I. Puzanov, B. Lestini, K. B. Nolop, R. J. Lee, A. K. Joe, C. J. Springer, J. A. Sosman, G. McArthu, R. S. Lo, A. Ribas, R. Marais (2012) RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors, New England Journal of Medicine, Jan 19 366(3):207-15 (Editorial in the same issue).
22. H. Shi, G. Moriceau, X. Kong, M-K Lee, F. Lee, R. C. Koya, C. Ng, T. Chodon, G. M. Pupo, K. Dahlman, J. A. Sosman, R. F. Kefford, G. V. Long, S. F. Nelson, A. Ribas, R. S. Lo (2012) Melanoma whole exome sequencing identifies gene amplification-mediated acquired resistance to vemurafenib, Nature Communications, Mar 6;3:a724. doi: 10.1038/ncomms1727 (News & Views in the same issue).
23. K.T. Paraiso, H.E. Haarberg, E. Wood, V.W.Rebecca, Y.A. Chen, Y. Xiang, A. Ribas, R. S. Lo, J.S. Weber, V.K. Sondak, J.K. John, A.S. Sarnaik, J.M. Koomen, K.S. Smalley (2012) The heat shock protein-90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms, Clinical Cancer Research, Feb 20. [Epub ahead of print].
24. H. Shi, G. Moriceau, X. Kong, R. Koya, R. Nazarian, A. Bacchiocchi, K. Dahlman, J. A. Sosman, R. Halaban, R. Kefford, G. V. Long, A. Ribas, and R. S. Lo (2012) Pre-existing MEK1 exon 3 mutations in V600E/KB-RAF melanomas do not confer resistance to B-RAF inhibitors, Cancer Discovery, May;2(5):414-424. Epub 2012 Apr 1. (In This Issue highlight).
25. N. A. Graham, M. Tahmasian, B. Kohli, E. Komisopoulou, M. Zhu, A. Ribas, R. S. Lo, I. K. Mellinghoff, P. S. Mischel and T. G. Graeber (2012) Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death, Molecular Systems Biology, Jun 26;8:589.
26. R. Strausman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub (2012) Tumor microenviroment contributes to RAF-inhibitor resistance through HGF secretion, Nature, 487(7408):500-4.
27. M. Krauthammer, Y. Kong, P. Evans, M. Choi, A. Bacchiocchi, B. Ha, J. P. McCusker, E. Cheng, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Raefski, M. Bosenberg, M. Sznol, H. M. Kluger, D. E. Brash, D. F. Stern, M. A. Materin, R. S. Lo, S. Mane, S. Ma, K. Kidd, N. K. Hayward, R. P. Lifton, J. Schlessinger, T. J. Boggon, R. Halaban (2012) A recurrent activating UV signature mutation in RAC1 in melanomas, Nature Genetics, Jul 29. doi: 10.1038/ng.2359. [Epub ahead of print]
28. A. Gembarska, F. Luciani, H. Shi, E. Russel, J. de Lange, D. Yip, J. Goydos, J. J. Haigh, L. Larue, A. Jochemsen, H. Shi, G. Moriceau, R. S. Lo, G. Ghanem, F. Bernal, J-C Marine (2012) MDM4 is a key therapeutic target in melanoma, Nature Medicine, Jul 22. doi: 10.1038/nm.2863. [Epub ahead of print]
29. A. Viros, R. Hayward, S. Yashar, C.C. Yu, M. Martin, A. Zambon, D. Niculescu-Duvaz, C. Springer, R. S, Lo and R. Marais (2012) Topical 5-fluorouracil induces regression of keratoacanthoma and squamous cell carcinoma secondary to BRAF inhibitors, Journal of Investigative Dermatology, Aug 16. doi: 10.1038/jid.2012.268. [Epub ahead of print]
30. J. S. Wilmott, V. Tembe, J. R. Howle, R. Sharma, J. F. Thompson, H. Rizos, R. S. Lo, R. F. Kefford, R. A. Scolyer, G. V. Long (2012) Intralesional molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine, Molecular Cancer Therapeutics, Sep 7. [Epub ahead of print].
31. K. Trunzer, A. C. Pavlick, L. Schuchter, R. Gonzalez, G. A. McArthur, T. E. Hutson, S. J. Moschoss, K. T. Flaherty, K. B. Kim, J. S. Weber, P. Hersey, R. Kefford, D. Lawrence, P. Ott, R. Amaravadi, K. Lewis, I. Puzanov, R. S. Lo, A. Koehler, M. Kockx, O. Spleiss, A. Schell-Steven, L. Cockey, K. Nolop, R. Lee, A. Joe, J. A. Sosman, A. Ribas (2013) Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma, Journal of Clinical Oncology, Apr 8. [Epub ahead of print]
32. S. Hou, L. Zhao, Q. Shen, J. Yu, C. Ng, X. Kong, D. Wu, M. Song, X. Shi, Clover X. Xu, W-H. OuYang, R. He, X-Z. Zhao, B. Xiong, T. Lee, C. Brunicardi, M. A. Garcia, A. Ribas, R. S. Lo and H-R. Tseng (2013) Polymer nanofiber-embedded microchips for detection, isolation and molecular analysis of single circulating melanoma cells, Angewandte Chemie, Mar 18;52(12):3379-83. doi: 10.1002/anie.201208452. Epub 2013 Feb 21.
33. R.S. Lo, A. Ribas, G.V. Long, R. Ballotti, M. Berger, H. Willy, G.T. Gibney, M. Bosenberg, E. Bernstein, J. Villanueva, K.S. Smalley (2013) Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California, Pigment Cell Melanoma Research, Apr 4. doi: 10.1111/pcmr.12103. [Epub ahead of print].
Referring a Patient to UCLA
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.
Find out how to refer a patient
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.
Find out how to refer a patient
Dr. Roger
Lo,
click here to update your profile.
